Scientists have discovered that disrupting the PirB receptor in the brain can lead to better neural rewiring in cases of lazy eye and other neural pathologies. The PirB molecule is also involved in immunity and may play a role in Alzheimer's disease. However, targeting the LilrB2 protein in humans, which is similar to PirB, may require disruption of multiple variants.